This product is still under development. Please contact us if you have interest in this product. We will accelerate the development process accordingly and reserve this product for you as request.
Multiple variants of SARS-CoV-2 are circulating globally and posting new challenges to human health. The variant B.1.351 identified in South Africa shows evidence of increased transmissibility and resistance to established immunity. There are 10 mutations on the spike protein of the South African variant (L18F, D80A, D215G, LAL242-244del, R246I, K417N, E484K, N501Y, D614G, A701V); of which 3 (K417N, E484K, N501Y) resides on the receptor-binding domain (RBD). To evaluate the impacts of the new variants, a rapid and effective assay kit detecting the levels of antibody against the mutant is in urgent need.
This kit is developed for serologic test for IgG titer of Anti-SARS-CoV-2 Spike RBD antibody in serum/plasma in vitro. The Spike RBD antigen used in this kit contains K417N, E484K, N501Y mutations found in the South African variant (known as B.1.351 or 20C/501Y.V2).